These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 17502835

  • 1. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
    Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H.
    Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
    [Abstract] [Full Text] [Related]

  • 2. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [Abstract] [Full Text] [Related]

  • 3. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
    Xie H, Griskevicius L, Ståhle L, Hassan Z, Yasar U, Rane A, Broberg U, Kimby E, Hassan M.
    Eur J Pharm Sci; 2006 Jan; 27(1):54-61. PubMed ID: 16183265
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.
    Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, Ishii I, Ishikawa T, Kitada M.
    Drug Metab Dispos; 2011 Nov; 39(11):2045-8. PubMed ID: 21821736
    [Abstract] [Full Text] [Related]

  • 6. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
    Dobrinas M, Crettol S, Oneda B, Lahyani R, Rotger M, Choong E, Lubomirov R, Csajka C, Eap CB.
    Pharmacogenet Genomics; 2013 Feb; 23(2):84-93. PubMed ID: 23249875
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
    Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, Brockmöller J.
    Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
    [Abstract] [Full Text] [Related]

  • 9. [Cyclophosphamide and CYP2B6].
    Torimoto Y, Kohgo Y.
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1090-3. PubMed ID: 18633247
    [Abstract] [Full Text] [Related]

  • 10. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
    Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.
    Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
    [Abstract] [Full Text] [Related]

  • 11. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.
    AIDS; 2007 Oct 18; 21(16):2191-9. PubMed ID: 18090046
    [Abstract] [Full Text] [Related]

  • 12. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
    Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH.
    Pharmacogenetics; 2004 Apr 18; 14(4):225-38. PubMed ID: 15083067
    [Abstract] [Full Text] [Related]

  • 13. Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.
    Shu W, Chen L, Hu X, Zhang M, Chen W, Ma L, Liu X, Huang J, Pang T, Li J, Zhang Y.
    J Clin Pharmacol; 2017 Jul 18; 57(7):886-898. PubMed ID: 28181240
    [Abstract] [Full Text] [Related]

  • 14. Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
    Shu W, Guan S, Yang X, Liang L, Li J, Chen Z, Zhang Y, Chen L, Wang X, Huang M.
    Br J Clin Pharmacol; 2016 Feb 18; 81(2):327-40. PubMed ID: 26456622
    [Abstract] [Full Text] [Related]

  • 15. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
    Walko CM, Combest AJ, Spasojevic I, Yu AY, Bhushan S, Hull JH, Hoskins J, Armstrong D, Carey L, Collicio F, Dees EC.
    Cancer Chemother Pharmacol; 2012 May 18; 69(5):1189-96. PubMed ID: 22245954
    [Abstract] [Full Text] [Related]

  • 16. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.
    Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P.
    Ann Hematol; 2011 Mar 18; 90(3):293-9. PubMed ID: 20878158
    [Abstract] [Full Text] [Related]

  • 17. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia.
    Iohom G, Ni Chonghaile M, O'Brien JK, Cunningham AJ, Fitzgerald DF, Shields DC.
    Eur J Anaesthesiol; 2007 Nov 18; 24(11):912-9. PubMed ID: 17555608
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.
    Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, Mizugaki M.
    Eur J Clin Pharmacol; 2002 Sep 18; 58(6):417-21. PubMed ID: 12242601
    [Abstract] [Full Text] [Related]

  • 20. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL, Kennedy MJ, Anderson LW, Kiraly SB, Black KC, Colvin OM, Grochow LB.
    Drug Metab Dispos; 1997 May 18; 25(5):544-51. PubMed ID: 9152592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.